PE20131035A1 - Formulacion de nevirapina de liberacion prolongada - Google Patents

Formulacion de nevirapina de liberacion prolongada

Info

Publication number: PE20131035A1
Authority: PE; Peru
Prior art keywords: nevirapin; formulation; prolonged release; anhydra; nevirapine
Prior art date: 2007-06-08

Application number

PE2013000070A

Other languages

English (en)

Spanish (es)

Inventor

Michael Cappola

Svetlana Sienkiewicz

Snow Glenn Charles

Feng-Jing Chen

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-08

Filing date

2008-06-06

Publication date

2013-10-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39739795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131035(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-06-06 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2013-10-01 Publication of PE20131035A1 publication Critical patent/PE20131035A1/es

Links

238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
230000002035 prolonged effect Effects 0.000 title 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 abstract 2
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 abstract 1
239000002552 dosage form Substances 0.000 abstract 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
229960003943 hypromellose Drugs 0.000 abstract 1
229960001021 lactose monohydrate Drugs 0.000 abstract 1
235000019359 magnesium stearate Nutrition 0.000 abstract 1
229960000689 nevirapine Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PE2013000070A 2007-06-08 2008-06-06 Formulacion de nevirapina de liberacion prolongada PE20131035A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US94276507P	2007-06-08	2007-06-08

Publications (1)

Publication Number	Publication Date
PE20131035A1 true PE20131035A1 (es)	2013-10-01

Family

ID=39739795

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PE2008000969A PE20090371A1 (es)	2007-06-08	2008-06-06	Formulacion de nevirapina de liberacion prolongada
PE2013000070A PE20131035A1 (es)	2007-06-08	2008-06-06	Formulacion de nevirapina de liberacion prolongada

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PE2008000969A PE20090371A1 (es)	2007-06-08	2008-06-06	Formulacion de nevirapina de liberacion prolongada

Country Status (28)

Country	Link
US (1)	US8460704B2 (de)
EP (1)	EP2155169B1 (de)
JP (1)	JP5417662B2 (de)
KR (1)	KR101017862B1 (de)
CN (1)	CN101784263B (de)
AR (1)	AR066924A1 (de)
AU (1)	AU2008262031B2 (de)
BR (1)	BRPI0811732A2 (de)
CA (1)	CA2687491C (de)
CL (1)	CL2008001678A1 (de)
CO (1)	CO6150128A2 (de)
DK (1)	DK2155169T3 (de)
EA (1)	EA018377B1 (de)
EC (1)	ECSP099561A (de)
ES (1)	ES2574836T3 (de)
HU (1)	HUE028598T2 (de)
IL (1)	IL199924A0 (de)
MA (1)	MA31430B1 (de)
MX (1)	MX2009007764A (de)
NZ (1)	NZ578664A (de)
PE (2)	PE20090371A1 (de)
PL (1)	PL2155169T3 (de)
TN (1)	TN2009000510A1 (de)
TW (1)	TWI419716B (de)
UA (1)	UA97971C2 (de)
UY (1)	UY31128A1 (de)
WO (1)	WO2008154234A2 (de)
ZA (1)	ZA200904939B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY149159A (en)	2005-11-15	2013-07-31	Hoffmann La Roche	Method for treating joint damage
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
BRPI0811732A2 (pt)	2007-06-08	2014-11-18	Boehring Ingelheim Internat Gmbh	Formulação de liberação prolongada de nevirapina
EP3412300A1 (de)	2008-06-27	2018-12-12	Duke University	Therapeutika mit elastinähnlichen peptiden
CA2835272A1 (en)	2011-05-30	2012-12-06	Cipla Limited	Pharmaceutical antiretroviral composition
CA2846209C (en) *	2011-08-24	2022-04-05	Phasebio Pharmaceuticals, Inc.	Systemic sustained release formulation comprising elastinlike peptide repeating sequence and protein active agent
IN2014MN01907A (de) *	2012-03-05	2015-07-10	Cipla Ltd
CN104523630B (zh) *	2015-01-22	2017-08-25	山东新时代药业有限公司	一种奈韦拉平片剂
EP3153157A1 (de)	2015-10-09	2017-04-12	Teva Pharmaceutical Works Private Limited Company	Pharmazeutische zusammensetzung zur verzögerten freisetzung von nevirapin

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5366972A (en) *	1989-04-20	1994-11-22	Boehringer Ingelheim Pharmaceuticals, Inc.	5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
US5133974A (en) *	1989-05-05	1992-07-28	Kv Pharmaceutical Company	Extended release pharmaceutical formulations
CA2030056C (en)	1989-11-17	1995-10-17	Karl D. Hargrave	5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection
US5419917A (en) *	1994-02-14	1995-05-30	Andrx Pharmaceuticals, Inc.	Controlled release hydrogel formulation
US6514530B2 (en) *	1997-09-09	2003-02-04	Alza Corporation	Dosage form comprising means for changing drug delivery shape
DK1035834T3 (da) *	1997-12-05	2002-07-08	Alza Corp	Osmotisk doseringsform omfattende en første og anden coating
WO2000035419A2 (en) *	1998-12-17	2000-06-22	Alza Corporation	Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
ES2255490T3 (es) *	1999-03-31	2006-07-01	Janssen Pharmaceutica N.V.	Almidon pregelatinizado en una formulacion de liberacion controlada.
CA2384188C (en) *	1999-09-24	2008-06-17	Janssen Pharmaceutica N.V.	Antiviral compositions
AU2084801A (en)	1999-12-09	2001-06-18	Alza Corporation	Antiviral medication
US6541014B2 (en) *	2000-10-13	2003-04-01	Advancis Pharmaceutical Corp.	Antiviral product, use and formulation thereof
WO2002092095A1 (en)	2001-05-11	2002-11-21	Boehringer Ingelheim International Gmbh	Use of nevirapine to treat or prevent lipid pathology in patients with hiv that is resistant to nevirapine
US20030050620A1 (en)	2001-09-07	2003-03-13	Isa Odidi	Combinatorial type controlled release drug delivery device
WO2004043435A2 (en)	2002-11-13	2004-05-27	Control Delivery Systems, Inc.	Systemic delivery of antiviral agents
CA2529852A1 (en)	2003-06-20	2004-12-29	Viral Genomix, Inc.	Compositions for and methods for treating hiv
AP1826A (en)	2003-10-01	2008-02-08	Lupin Ltd	A controlled release pharmaceutical composition and a process for preparing the same
NZ581461A (en)	2003-11-13	2011-04-29	Psivida Inc	Injectable sustained release delivery devices
CA2577288C (en) *	2004-09-02	2010-11-30	Janssen Pharmaceutica N.V.	Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
WO2006114709A1 (en) *	2005-04-25	2006-11-02	Aurobindo Pharma Limited	Pharmaceutical compositions of antiretrovirals
WO2007000779A2 (en)	2005-06-29	2007-01-04	Panacea Biotec Ltd.	Pharmaceutical sustained release compositions and processes thereof
US9198862B2 (en) *	2005-07-22	2015-12-01	Rubicon Research Private Limited	Dispersible tablet composition
FR2891459B1 (fr) *	2005-09-30	2007-12-28	Flamel Technologies Sa	Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
JP2009511191A (ja) *	2005-10-14	2009-03-19	マイクロドース・テクノロジーズ・インコーポレーテッド	経口投与剤組合せ型医薬パッケージ法
BRPI0811732A2 (pt)	2007-06-08	2014-11-18	Boehring Ingelheim Internat Gmbh	Formulação de liberação prolongada de nevirapina

2008
- 2008-06-04 BR BRPI0811732-2A2A patent/BRPI0811732A2/pt not_active IP Right Cessation
- 2008-06-04 DK DK08756672.5T patent/DK2155169T3/en active
- 2008-06-04 JP JP2009552940A patent/JP5417662B2/ja active Active
- 2008-06-04 NZ NZ578664A patent/NZ578664A/en not_active IP Right Cessation
- 2008-06-04 AU AU2008262031A patent/AU2008262031B2/en not_active Ceased
- 2008-06-04 ES ES08756672.5T patent/ES2574836T3/es active Active
- 2008-06-04 UA UAA200908230A patent/UA97971C2/ru unknown
- 2008-06-04 KR KR1020097016610A patent/KR101017862B1/ko active Active
- 2008-06-04 MX MX2009007764A patent/MX2009007764A/es active IP Right Grant
- 2008-06-04 PL PL08756672.5T patent/PL2155169T3/pl unknown
- 2008-06-04 WO PCT/US2008/065705 patent/WO2008154234A2/en not_active Ceased
- 2008-06-04 HU HUE08756672A patent/HUE028598T2/en unknown
- 2008-06-04 US US12/523,226 patent/US8460704B2/en active Active
- 2008-06-04 CN CN2008800193577A patent/CN101784263B/zh active Active
- 2008-06-04 EA EA200900958A patent/EA018377B1/ru not_active IP Right Cessation
- 2008-06-04 CA CA2687491A patent/CA2687491C/en active Active
- 2008-06-04 EP EP08756672.5A patent/EP2155169B1/de not_active Revoked
- 2008-06-06 CL CL2008001678A patent/CL2008001678A1/es unknown
- 2008-06-06 PE PE2008000969A patent/PE20090371A1/es not_active Application Discontinuation
- 2008-06-06 UY UY31128A patent/UY31128A1/es not_active Application Discontinuation
- 2008-06-06 TW TW097121294A patent/TWI419716B/zh active
- 2008-06-06 AR ARP080102446A patent/AR066924A1/es unknown
- 2008-06-06 PE PE2013000070A patent/PE20131035A1/es not_active Application Discontinuation
2009
- 2009-07-15 ZA ZA200904939A patent/ZA200904939B/xx unknown
- 2009-07-16 IL IL199924A patent/IL199924A0/en unknown
- 2009-07-21 CO CO09075419A patent/CO6150128A2/es unknown
- 2009-08-05 EC EC2009009561A patent/ECSP099561A/es unknown
- 2009-12-04 TN TNP2009000510A patent/TN2009000510A1/fr unknown
- 2009-12-07 MA MA32400A patent/MA31430B1/fr unknown

Also Published As

Publication number	Publication date
JP2010520891A (ja)	2010-06-17
EA018377B1 (ru)	2013-07-30
ECSP099561A (es)	2009-09-29
KR20100020447A (ko)	2010-02-22
US20100278918A1 (en)	2010-11-04
TWI419716B (zh)	2013-12-21
CL2008001678A1 (es)	2009-09-11
TW200916127A (en)	2009-04-16
JP5417662B2 (ja)	2014-02-19
IL199924A0 (en)	2010-04-15
MA31430B1 (fr)	2010-06-01
ES2574836T3 (es)	2016-06-22
CA2687491A1 (en)	2008-12-18
DK2155169T3 (en)	2016-06-13
ZA200904939B (en)	2010-04-28
BRPI0811732A2 (pt)	2014-11-18
PL2155169T3 (pl)	2016-09-30
WO2008154234A2 (en)	2008-12-18
EA200900958A1 (ru)	2010-04-30
AU2008262031A1 (en)	2008-12-18
CN101784263A (zh)	2010-07-21
MX2009007764A (es)	2009-09-10
WO2008154234A3 (en)	2010-01-21
CA2687491C (en)	2011-09-20
US8460704B2 (en)	2013-06-11
AU2008262031B2 (en)	2011-08-25
EP2155169A2 (de)	2010-02-24
KR101017862B1 (ko)	2011-03-04
CN101784263B (zh)	2012-11-07
WO2008154234A9 (en)	2009-11-26
NZ578664A (en)	2011-11-25
HK1145806A1 (en)	2011-05-06
HUE028598T2 (en)	2016-12-28
AR066924A1 (es)	2009-09-23
CO6150128A2 (es)	2010-04-20
TN2009000510A1 (en)	2011-03-31
EP2155169B1 (de)	2016-03-23
PE20090371A1 (es)	2009-04-24
UY31128A1 (es)	2009-01-30
UA97971C2 (ru)	2012-04-10

Legal Events

Date	Code	Title	Description
2016-01-26	FD	Application declared void or lapsed

Publication	Publication Date	Title
PE20131035A1 (es)	2013-10-01	Formulacion de nevirapina de liberacion prolongada
CO6440564A2 (es)	2012-05-15	Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
CL2011001621A1 (es)	2012-03-30	Composicion farmaceutica oral de liberacion sostenida que comprende en una forma de dosificacion unitaria, una matriz hidrofilica, un opioide, una sal de un aine, y opcionalmente un surfactante aniónico; y uso para preparar medicamentos utiles en la prevencion, alivio o disminución del nivel del dolor y supresión de la tos.
MA29115B1 (fr)	2007-12-03	Produits pharmaceutiques solides, administres par voie orale et contenant du rivaroxaban, a liberation modifiee
MX2008012731A (es)	2008-10-14	Tabletas de paracetamol de liberacion rapida.
AR065096A1 (es)	2009-05-13	Preparacion solida
PE20241581A1 (es)	2024-08-01	Formas cristalinas de un inhibidor de tirosina quinasa de bruton
CO6400186A2 (es)	2012-03-15	Tabletas de acetato de ulipristal
AR065809A1 (es)	2009-07-01	Formulaciones farmaceuticas que contienen un inhibidor sglt2
IL192773A0 (en)	2009-02-11	Microparticulate pharmaceutical forms resistant to immediate release of the active ingredient in the presence of alcohol
NO20070887L (no)	2007-03-19	Kornformet farmasoytisk preparat med tidsbegrenset frigivelse for oral administrasjon, og intraoral hurtig desintegrerende tablett som inneholder preparatet
ES2916604T1 (es)	2022-07-04	Ensayos de detección de nrf2 y métodos y composiciones relacionados
MX2012003551A (es)	2012-08-03	Tabletas transformables via oral.
UA116334C2 (uk)	2018-03-12	Тверді форми дозування бендамустину
ATE540680T1 (de)	2012-01-15	Pharmazeutische aripiprazol-zusammensetzungen
IL195931A0 (en)	2009-09-01	Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and methods for its production
CL2013000677A1 (es)	2013-07-19	Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn.
AR077546A1 (es)	2011-09-07	Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos
DOP2011000406A (es)	2012-04-15	Composiciones de dosis fijas farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion en terapeutica
TN2015000135A1 (en)	2016-10-03	Modified release formulations for oprozomib
CO6150126A2 (es)	2010-04-20	Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina
BRPI0615989B8 (pt)	2021-05-25	formulação farmacêutica de dosagem oral
JO3587B1 (ar)	2020-07-05	أشكال جرعات بينداموستين عن طريق الفم
AR080256A1 (es)	2012-03-21	Formulaciones farmaceuticas solidas de ramipril y besilato de amlodipino y su preparacion
TR201001903A2 (tr)	2011-04-21	Uzatılmış salımlı tiyokolşiklozit tablet.